report-bg

Cell Line Development Market Analysis by Product {Equipment (Incubators, Centrifuges, Bioreactors, Storage Equipment, and Others), and Media & Reagents}; by Cell Type (CHO Cells, BHK 21 Cells, NSO Cells, Murine C127 Cells, NIH3T3 Cells, L929 Cells, and Other Cells); by Application (Bioproduction, Tissue Engineering, Regenerative Medicine, Biologics, and Others); and by Industry (Biotechnology, Biopharma, and Academia) – Global Supply & Demand Analysis & Opportunity Outlook 2021-2031

Buy Now Report ID: 713 | Published Date: Feb 10, 2023

Global Cell Line Development Market TOC

  1. Market Definition and Research Methodology
    1. Market Definition and Segmentation
    2. Assumptions and Acronyms
    3. Research Objectives
    4. Research Methodology
  2. Executive Summary – Global Cell Line Development Market
    1. Market Size and Forecast
    2. Competitive Landscape
    3. Market Dynamics
    4. Regional Opportunity Analysis
    5. Recent Advancements in Cell Line Development Market
    6. Opportunity Analysis
  3. Industry Value Chain Analysis
    1. Manufactures
    2. Supplier and Distributors
    3. End-Users
  4. Market Dynamics
    1. Drivers
    2. Challenges
    3. Trends
    4. Opportunities
  5. Regulatory and Standards Landscape
    1. Standards and Compliances by Regulatory Bodies (US FDA, EMA, PMDA, TGA and Others)
    2. Regulatory Impact on the Cell line Development Market
  6. Industry Risk Analysis in Cell Line Development Workflow Environment
  7. Trends in Cell Line Development
    1. Application of Computational Fluid Dynamics Modeling Leads to Scaling-Up of Cell Production
    2. Harnessing of Omics and Bioinformatic Analysis in Clone Selection
    3. Others
  8. Process Technology Workflow
    1. Transfection Methods Used in CLD (Transient Transfection; Stable Transfection (Electroporation; Viral Transfection and Others)
    2. Single Cell Isolation Techniques (Limiting Dilution; Flow Cytometry; Others)
    3. Selection Methods (Antibiotic Resistance (G418, and Others)
    4. Assurance of Clonality (Imaging; Others)
    5. Scale-Up
    6. Titer of Recombinant Antibody
  9. Impact of COVID-19 on Global Cell Line Development Market
    1. Impact on Cell Line Development Manufacturers
    2. Impact on the Demand
    3. Impact on Distributers and Suppliers
    4. Impact on End Users
    5. Impact on New Entrants in the Market
    6. Impact on the Biotechnology and Healthcare Industry
  10. Workflow Timeline Analysis
  11. Cell Isolation Technology
    1. Current Market Players Analysis w.r.t Industry (Biotechnology, BioPharma and Academia)
  12. Technology Type for Gene Transfer in Cell Isolation Workflow
  13. Challenges in Cell Line Development Workflow Environment
    1. Formation of Stable CHO Production Cell Lines.
    2. Introduction of Advanced Biologics such as Trivalent T-cell Engagers and Antibody Cytokine Fusions.
    3. Others
  14. Competitive Landscape
    1. Market Share Analysis, 2021
    2. Competitive Benchmarking
    3. Biotechnology & Biopharmaceutical Company Profiles
      1. Lonza Group Ltd.
        1. Detailed Overview
        2. Assessment of Key Offering
        3. Analysis on Growth Strategies
        4. Exhaustive Analysis on Key Financial Indicators
        5.  Recent Developments
      2. Thermo Fisher Scientific
      3. Corning Incorporated
      4. General Electric Company
      5. Sartorius AG
      6. Selexis SA
      7. Merck KGaA
      8. WuXi AppTec
    4. Academia Profiles
      1. American Type Culture Collection (ATCC)
      2. European Collection of Cell Cultures (ECACC)
  15. Global Cell Line Development Market 2021-2031
    1. Market Overview
    2. Market by Value (USD million)
    3. Market Segmentation by
      1. Product
        1. Equipment, 2021-2031F (USD million)
          1. Incubators, 2021-2031F (USD million)
          2. Centrifuges, 2021-2031F (USD million)
          3. Bioreactors, 2021-2031F (USD million)
          4. Storage Equipment, 2021-2031F (USD million)
          5. Others, 2021-2031F (USD million)
        2. Media and Reagents, 2021-2031F (USD million)
      2. Cell Type
        1. CHO Cells, 2021-2031F (USD million)
        2. BHK 21 Cells, 2021-2031F (USD million)
        3. NSO Cells, 2021-2031F (USD million)
        4. Murine C127 Cells, 2021-2031F (USD million)
        5. NIH3T3 Cells, 2021-2031F (USD million)
        6. L929 Cells, 2021-2031F (USD million)
        7. Other Cells, 2021-2031F (USD million)
      3. Application
        1. Bioproduction, 2021-2031F (USD million)
        2. Tissue Engineering, 2021-2031F (USD million)
        3. Regenerative Medicine, 2021-2031F (USD million)
        4. Biologics, 2021-2031F (USD million)
        5. Medicines, 2021-2031F (USD million)
        6. Toxicity Testing, 2021-2031F (USD million)
        7. Research, 2021-2031F (USD million)
        8. Drug Discovery, 2021-2031F (USD million)
        9. Cell Therapies, 2021-2031F (USD million)
        10. Gene Therapies, 2021-2031F (USD million)
      4. Industry
        1. Biotechnology, 2021-2031F (USD million)
        2. BioPharma, 2021-2031F (USD million)
        3. Academia, 2021-2031F (USD million)
      5. Industry Cross Analysis w.r.t. to Cell Type and Applications
      6. By Region
        1. North America, 2021-2031F (USD million)
        2. Europe, 2021-2031F (USD million)
        3. Asia Pacific, 2021-2031F (USD million)
        4. Latin America, 2021-2031F (USD million)
        5. Middle East & Africa, 2021-2031F (USD million)
  16. North America Cell Line Development Market 2021-2031
    1. Market Overview
    2. Market by Value (USD million)
    3. Market Segmentation by
      1. Product
        1. Equipment, 2021-2031F (USD million)
          1. Incubators, 2021-2031F (USD million)
          2. Centrifuges, 2021-2031F (USD million)
          3. Bioreactors, 2021-2031F (USD million)
          4. Storage equipment, 2021-2031F (USD million)
          5. Other, 2021-2031F (USD million)
        2. Media and Reagents, 2021-2031F (USD million)
      2. Cell Type
        1. CHO Cells, 2021-2031F (USD million)
        2. BHK 21 Cells, 2021-2031F (USD million)
        3. NSO Cells, 2021-2031F (USD million)
        4. Murine C127 Cells, 2021-2031F (USD million)
        5. NIH3T3 Cells, 2021-2031F (USD million)
        6. L929 Cells, 2021-2031F (USD million)
        7. Other Cells, 2021-2031F (USD million)
      3. Application
        1. Bioproduction, 2021-2031F (USD million)
        2. Tissue Engineering, 2021-2031F (USD million)
        3. Regenerative Medicine, 2021-2031F (USD million)
        4. Biologics, 2021-2031F (USD million)
        5. Medicines, 2021-2031F (USD million)
        6. Toxicity Testing, 2021-2031F (USD million)
        7. Research, 2021-2031F (USD million)
        8. Drug Discovery, 2021-2031F (USD million)
        9. Cell Therapies, 2021-2031F (USD million)
        10. Gene Therapies, 2021-2031F (USD million)
      4. Industry
        1. Biotechnology, 2021-2031F (USD million)
        2. BioPharma, 2021-2031F (USD million)
        3. Academia, 2021-2031F (USD million)
      5. By Country
        1. United States, 2021-2031F (USD million)
        2. Canada, 2021-2031F (USD million)
  17. Europe Cell Line Development Market 2021-2031
    1. Market Overview
    2. Market by Value (USD million)
    3. Market Segmentation by
      1. By Product
      2. By Cell Type
      3. By Application
      4. By Industry
      5. By Country
        1. United Kingdom, 2021-2031F (USD million)
        2. Germany, 2021-2031F (USD million)
        3. France, 2020-2030F (USD million)
        4. Italy, 2021-2031F (USD million)
        5. Spain, 2021-2031F (USD million)
        6. Russia, 2021-2031F (USD million)
        7. Netherlands, 2020-2030F (USD million)
        8. Rest of Europe, 2021-2031F (USD million)
      6. Industry Cross Analysis w.r.t. to Cell Type and Applications
  18. Asia Pacific Cell Line Development Market 2021-2031
    1. Market Overview
    2. Market by Value (USD million)
    3. Market Segmentation by
      1. By Product
      2. By Cell Type
      3. By Application
      4. By Industry
      5. By Country
        1. China, 2021-2031F (USD million)
        2. India, 2021-2031F (USD million)
        3. Japan, 2021-2031F (USD million)
        4. South Korea, 2021-2031F (USD million)
        5. Singapore, 2021-2031F (USD million)
        6. Australia, 2021-2031F (USD million)
        7. Rest of Asia Pacific, 2021-2031F (USD million)
      6. Industry Cross Analysis w.r.t. to Cell Type and Applications
  19. Latin America Cell Line Development Market 2021-2031
    1. Market Overview
    2. Market by Value (USD million)
    3. Market Segmentation Analysis 2021-2031
      1. By Product
      2. By Cell Type
      3. By Application
      4. By Industry
      5. By Country
        1. Brazil, 2021-2031F (USD million)
        2. Mexico, 2021-2031F (USD million)
        3. Argentina, 2021-2031F (USD million)
        4. Rest of Latin America, 2021-2031F (USD million)
      6. Industry Cross Analysis w.r.t. to Cell Type and Applications
  20. Middle East & Africa Cell Line Development Market 2021-2031
    1. Market Overview
    2. Market by Value (USD million)
    3. Market Segmentation Analysis 2021-2031
      1. By Product
      2. By Cell Type
      3. By Application
      4. By Industry
      5. By Country
        1. GCC, 2021-2031F (USD million)
        2. Israel, 2020-2030F (USD million)
        3. South Africa, 2021-2031F (USD million)
        4. Rest of Middle East & Africa, 2021-2031F (USD million)
      6. Industry Cross Analysis w.r.t. to Cell Type and Applications
  21. Analyst Recommendation based on
    1. Cell type
    2. Application
    3. Gene Transfer Technology Types
    4. Cell Isolation Technology

Global Cell Line Development Market Regional Synopsis

Regionally, the global cell line development market is studied into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Amongst these markets, the market in Asia Pacific is projected to hold the market share of USD 3,945.1 Million by the end of 2031, up from a revenue of USD 1,166.9 Million in the year 2021. Further, the market in Asia Pacific is expected to grow at the highest CAGR of 13.02% over the forecast period. Besides this the market in North America is projected to garner the largest revenue of USD 5,086.7 Million by the end of 2031, backed by increasing investments and funds made available to manufacturing businesses and academic & research institutions to develop cell line-based end products like precision medicine and other treatments. In 2018, the National Institutes of Health's All of Us Research Program funded Genome Centers to generate genotype sequencing data from bio samples. To aid researchers in their quest to better understand how genetics, environment, and lifestyle choices affect health outcomes, they seek to create a varied network of more than 1 million participant partners across the US. In the upcoming years, it is anticipated that these factors will encourage market expansion.

The study further incorporates Y-O-Y Growth, market opportunities, demand & supply and forecast future opportunity in North America (United States, Canada, Mexico), South America, Europe (U.K., Germany, France, Italy, Spain, Hungary, BENELUX [Belgium, Netherlands, Luxembourg], NORDIC [Norway, Denmark, Sweden, Finland], Poland, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Indonesia, Taiwan, Hong Kong, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa).


RN
Cell-Line-Development-Market
Get more information on this report: Request Free Sample PDF

Global Cell Line Development Market: Growth Drivers and Challenges

Growth Drivers

  • Rising Burden of Osteoporosis

According to the International Osteoporosis Foundation, every year, osteoporosis causes more than 8.9 million fractures worldwide, culminating in an osteoporosis fracture every 3 seconds.

To deal with growing osteoporosis monoclonal antibodies are prepared which is known are stimulating antibodies in patient. Hence owing to this the market is expected to boost in the forecast period.

  • Growing Risk of Coronavirus

As of February 2022, there had been approximate 5 million confirmed deaths due to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) worldwide, which has caused over 400 million cases.

  • Increasing Risk of Cancer Causing Disease

According to the World Health Organization, about 30% of cancer cases in low- and lower-middle-income nations are caused by cancer-causing diseases such the human papillomavirus (HPV) and hepatitis.

  • Growing Nervous Systems Disorder Cases

According to the European Academy of Neurology, over the past 30 years, the incidence of deaths from neurological disorders has climbed by approximately 40%, with 1 in 3 persons experiencing a neurological ailment at some point in their lives.

  • Cell Line Development Based On Mammalian Cell Culture

Mammalian cell culture has recently become essential to the biomanufacturing of viral vaccines and therapeutic proteins. Through viral infection, these cells create vaccines, and through genetic engineering, they produce therapeutic proteins.

Challenges

  • Inability to Produce or Develop a Stable and Authentic Cell
  • Low Transfection Efficiency
  • Integration Frequency

Stable cell lines are a crucial laboratory tool for screening experimental medications, researching gene function, and generating therapeutic proteins because they express significant amounts of the protein of interest. However, a variety of elements, including the use of a DNA vector, reagents, the choice of cell lines, and the transfection technique, are equally crucial in creating a stable cell line. Additionally, the stability of cell lines will suffer from any modifications or adjustments to these variables. Hence this factor could hinder the growth of the market.

The global cell line development market is segmented and analysed for demand and supply by cell type into CHO cells, BHK 21 cells, NSO cells, murine C127 cells, NIH3T3 cells, L929 cells, and others. Out of which, BHK 21 cells segment is anticipated to garner the revenue of USD 2,455.4 Million by the end of 2031, by growing at a highest CAGR of 12.84% during the forecast period. In 2021 the revenue of BHK 21 cells segment stood at USD 737.8 Million.  Increasing cases of rabies is expected to boost the market growth. BHK 21 cells are most frequently used cells lines. They are extensively used for treating rabies. The World Organization for Animal Health use these BHK21 cells in the regular diagnosis of rabies. To thrive in serum- or animal-component-free cell medium for the manufacture of rabies vaccines, BHK21 cells appear to have already undergone the necessary adaptations. Additionally CHO cells segment is anticipated to garner the largest revenue of USD 5,396.4 Million by the end of 2031.


Market Segmentation

Market-Growth-Drivers

Our in-depth analysis of the global cell line development market includes the following segments:

By Product

  • Equipment
    • Incubators
    • Centrifuges
    • Bioreactors
    • Storage Equipment
    • Others
  • Media & Reagents

By Cell Type

  • CHO Cells
  • BHK 21 Cells
  • NSO Cells
  • Murine C127 Cells
  • NIH3T3 Cells
  • L929 Cells
  • Other Cells

By Application

  • Bioproduction
  • Tissue Engineering
  • Regenerative Medicine
  • Biologics
  • Medicines
  • Toxicity Testing
  • Research
  • Drug Discovery
  • Cell Therapies
  • Gene Therapies

By Industry

  • Biotechnology
  • Biopharma
  • Academia


Get more information on this report: Request Free Sample PDF

Top Featured Companies Dominating The Market

top-features-companies

    Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global cell line development market that are included in our report are Lonza Group Ltd., Thermo Fisher Scientific, Corning Incorporated, General Electric Company, Sartorius AG, Selexis SA, Merck KGaA, WuXi AppTec, and others. The market research report also covers an in-depth analysis of the academia organizations who are associated with cell line development, the profiling of which includes organizations such as American Type Culture Collection (ATCC), and European Collection of Authentic Cell Cultures.


In-the-news

In The News

  • Lonza Group Ltd. collaborates with Vineti to improve "Vein-to-Vein" delivery service across its manufacturing network for cell and gene therapy.
  • Moderna Inc. and Thermo Fisher Scientific signed a long-term agreement in February 2022 for the production of the COVID-19 vaccine and other investigational drugs based on mRNA technology.

preview-analysis

Global Economic Impact

Request Insights
Despite Inflation & Fearing Recession, Businesses Across the Globe Expected to Do Better in 2023:

In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.


Author Credits:  Radhika Gupta, Shivam Bhutani


Key Questions Answered in the Report

1) What are the major factors driving the growth of the cell line development services market?

Ans: The factors driving the growth of the market are rising burden of osteoporosis, growing risk of coronavirus, increasing risk of cancer, and others.

2) What would be the CAGR of cell line development services market over the forecast period?

Ans: The market is anticipated to attain a CAGR of 12.39% over the forecast period, i.e., 2022 – 2031.

3) What are the challenges affecting the cell line development services market growth?

Ans: Inability to produce or develop a stable and authentic cell, low transfection efficiency, and integration frequency are some of the major factors expected to hider the growth of the market.

4) Which region will provide more business opportunities for growth of cell line development services market in future?

Ans: The market in Asia Pacific is projected to hold the largest market share by the end of 2031 and provide more business opportunities in the future.

5) Who are the major players dominating the cell line development services market?

Ans: The major players in the market are Lonza Group Ltd., Thermo Fisher Scientific, Corning Incorporated, General Electric Company, and more.

6) How are the company profiles selected?

Ans: The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

7) What are the segments in the cell line development market?

Ans: The market is segmented by product, cell type, application, industry, and by region.

8) Which segment captures the largest market size in cell type in the cell line development market?

Ans: The BHK 21 cells is anticipated to garner the largest market size by the end of 2031 and display significant growth opportunities.

Let Us Hear About Your Requirements:

Submit Your Request For Proposal (RFP)

 Request Free Sample Copy